Cargando…
Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
Autores principales: | Zandi, Milad, Behboudi, Emad, Soltani, Saber |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312046/ https://www.ncbi.nlm.nih.gov/pubmed/34325045 http://dx.doi.org/10.1016/j.ijid.2021.07.053 |
Ejemplares similares
-
Role of Glycoprotein Hemagglutinin-Esterase in COVID-19 Pathophysiology?
por: Zandi, Milad, et al.
Publicado: (2021) -
Ribosome Profiling: A Useful Approach to Discover Hidden
Corners of SARS-CoV-2
por: Zandi, Milad, et al.
Publicado: (2022) -
miR-200c-3p upregulation and ACE2 downregulation via bacterial LPS and LTA as interesting aspects for COVID-19 treatment and immunity
por: Soltani, Saber, et al.
Publicado: (2021) -
Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19
por: Zandi, Milad, et al.
Publicado: (2021) -
Comment on Alfassam et al. Development of a Colorimetric Tool for SARS-CoV-2 and Other Respiratory Viruses Detection Using Sialic Acid Fabricated Gold Nanoparticles. Pharmaceutics 2021, 13, 502
por: Zandi, Milad, et al.
Publicado: (2022)